Shingles (Herpes zoster) vaccine uptake for 2014-15

Publication Date: 05 January 2016

​​​​In September 2013 the Scottish Government launched the first national shingles immunisation campaign using Zostavax, which is a live attenuated vaccine. It is derived from the Oka strain of VZV and has significantly higher antigen content than the varicella vaccine. 

In 2014 to 2015, the second year of the programme, the vaccine was offered to non-immunocompromised adults aged 70 years and also rolled out as part of an ongoing catch-up programme to 78 and 79 year olds. Those who had turned 70 in the first year of the programme but who had not yet received the vaccine also remained eligible. 

  • ​Uptake in those aged 70 years (routine cohort) was 58.7% compared with 59.7% in 2013 to 2014 and ranged from 48.0% to 64.9% across NHS boards. 
  • Uptake in those aged 78 years was 54.9% (no comparable data from 2013 to 2014) and ranged from 29.9% to 76.6% by NHS board. 
  •  Uptake in those aged 79 years was 55.0% compared with 55.6% in 2013 to 2014 and ranged from 44.7% to 65.1% by NHS board.​

Resource information

Publisher:
Health Protection Scotland
Publication type:
Surveillance Report